These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Previously untreated patients and recombinant factor VIII concentrate studies. Pasi KJ Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534 [TBL] [Abstract][Full Text] [Related]
4. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Kessler CM; Ludlam CA Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193 [No Abstract] [Full Text] [Related]
5. Recombinant factor VIII in hemophilia. Cohen A; Butler R N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552 [No Abstract] [Full Text] [Related]
6. Factor VIII inhibitor and severity of hemophilia. Schoppmann A; Waytes AT Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549 [No Abstract] [Full Text] [Related]
8. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. van der Bom JG; Gouw SC; Rosendaal FR Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628 [No Abstract] [Full Text] [Related]
9. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234 [No Abstract] [Full Text] [Related]
11. Diagnosis of factor VIII versus nonspecific inhibitors. Goldsmith JC Semin Hematol; 1993 Apr; 30(2 Suppl 1):3-6. PubMed ID: 8480195 [No Abstract] [Full Text] [Related]
12. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia. Werwitzke S; Tiede A; Stoll M; von Depka M J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985 [No Abstract] [Full Text] [Related]
13. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Monahan PE; Aledort LM; Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804 [TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Hedner U Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747 [No Abstract] [Full Text] [Related]
15. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Mauz-Korholz C; Korholz D; Gobel U Thromb Haemost; 1997 Aug; 78(2):959. PubMed ID: 9268203 [No Abstract] [Full Text] [Related]
16. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia]. Wu RH; Wei QQ Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299 [No Abstract] [Full Text] [Related]
17. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Hoyer LW; Scandella D Semin Hematol; 1994 Apr; 31(2 Suppl 4):1-5. PubMed ID: 7524160 [No Abstract] [Full Text] [Related]
18. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity. Watts RG Am J Hematol; 2005 May; 79(1):58-60. PubMed ID: 15849767 [TBL] [Abstract][Full Text] [Related]
19. Management of factor VIII inhibitors. Acharya SS; DiMichele DM Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541 [TBL] [Abstract][Full Text] [Related]
20. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Lollar P Thromb Haemost; 1997 Jul; 78(1):647-51. PubMed ID: 9198232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]